Date: September 03, 2026

KMP / Board / Auditor Changes

Not Specified

Dividend Declaration or Non-Declaration

Not Specified

Board Meeting Outcomes

Not Specified

Financial Results (Standalone & Consolidated)

Not Specified

Disinvestment / Strategic Actions

Not Specified

Other Operational / Legal / Strategic Disclosures

Code of Fair Disclosure Practices Adoption

  • Symbiotec Pharmalab Limited has formally adopted its Code of Practices and Procedures for Fair Disclosure of Unpublished Price Sensitive Information (UPSI)
  • The code is framed under Regulation 8(1) of the SEBI (Prohibition of Insider Trading) Regulations, 2015
  • Effective date of the policy: December 15, 2025

Policy Objectives and Principles

  • Company endeavors to preserve confidentiality of unpublished price sensitive information and prevent its misuse
  • Code ensures timely and adequate disclosure of UPSI that would impact security prices
  • Maintains uniformity, transparency and fairness in dealing with all stakeholders
  • Company will promptly disclose publicly any UPSI that would impact price discovery
  • Information will be uniformly and universally disseminated in timely manner to avoid selective disclosure
  • Press releases considered important for general public will be disclosed on company website
  • Quarterly and annual financial results and investor presentations will be posted on company website

Information Sharing Protocols

  • UPSI may be shared on need-to-know basis for legitimate purposes in ordinary course of business
  • Legitimate purposes include sharing with partners, collaborators, lenders, customers, suppliers, merchant bankers, legal advisors, auditors, insolvency professionals
  • Any person receiving UPSI pursuant to legitimate purpose shall be considered an "insider" under SEBI PIT Regulations

Chief Investor Relations Officer (CIRO)

  • Board of Directors has appointed a CIRO who reports to Chief Financial Officer
  • CIRO responsible for compliance with Fair Disclosure Code
  • CIRO contact email: secretarial@symbiotec.com
  • Employees are prohibited from responding to enquiries from stock exchanges, media or others unless authorized by CIRO or CFO

Policy Review and Governance

  • Policy framed based on provisions of SEBI PIT Regulations
  • In case of conflict, SEBI PIT Regulations or statutory enactments prevail over this policy
  • Subsequent amendments to SEBI PIT Regulations automatically apply to this policy
  • Changes or modifications to policy require approval by Board of Directors